Remedent, Inc. - Current report filing (8-K)

Table of Contents

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 10, 2008

REMEDENT, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-15975		86-0837251
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
Xavier de Cocklaan 42, 9831, Deurle, Belgium				N/A
(Address of Principal Executive Offices)				(Zip Code)

011-329-321-7080

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

TABLE OF CONTENTS

Item 1.01 Entry into a Material Definitive Agreement
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Item 9.01. Financial Statements and Exhibits
SIGNATURE
EXHIBIT INDEX
EXHIBIT 10.1
EXHIBIT 99.1

---

Table of Contents

SECTION 1 — REGISTRANT’S BUSINESS AND OPERATIONS

Item 1.01 Entry into a Material Definitive Agreement.

On April 10, 2008, Remedent N.V., a Belgian company and a subsidiary of Remedent, Inc. (“Company”), entered into a distribution agreement (“Agreement”) with GlamTech USA, Inc., a corporation under the laws of Delaware (“GlamTech”) whereby GlamTech agreed to be the exclusive distributor of the Company’s GlamSmile products in the United States of America and Canada.

The term of the Agreement will be for five years and will begin on April 10, 2008.

The Agreement is filed as Exhibit 10.1 to this Form 8-K. As the Company has applied for confidential treatment from the Securities and Exchange Commission with respect to certain commercially sensitive pricing terms contained in the Agreements, such terms have been redacted from Exhibit 10.1 and have been replaced by the symbol “[ *** ].”

For further information see the Agreement attached hereto as Exhibit 10.1.

SECTION 5—CORPORATE GOVERNANCE AND MANAGEMENT

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective April 30, 2008, Roger Leddington is resigning his position as Senior Vice President and Head of US Marketing for Remedent. Mr. Leddington guided GlamSmile’s entry into the US market late last year, and in conjunction with the GlamTech USA, Inc. Distribution Agreement, Mr. Leddington accepted the position as GlamTech’s President.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01. Financial Statements and Exhibits.

Exhibit No.				Exhibit Description
	10.1			Distribution Agreement, dated April 10, 2008, by and between Remedent n.v and GlamTech USA, Inc. *
	99.1			Press Release dated April 15, 2008, “Remedent, Inc. Announces launch of Exclusive Strategic Marketing Program with GlamTech USA, Inc. for the Distribution of Glamsmile™ in the United States and Canada”

 

*		Application has been made to the Securities and Exchange Commission to seek confidential treatment of certain portions of this Exhibit 10.1 under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omitted material for which confidential treatment has been requested has been filed separately with the Securities and Exchange Commission.

 

---

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REMEDENT, INC. , a Nevada corporation
Dated: April 14, 2008	By:	/s/ Robin List
		Robin List,
		Chief Executive Officer

 

---

Table of Contents

EXHIBIT INDEX

Exhibit No.				Exhibit Description
	10.1			Distribution Agreement, dated April 10, 2008, by and between Remedent n.v and GlamTech USA, Inc. *
	99.1			Press Release dated April 15, 2008, “Remedent, Inc. Announces launch of Exclusive Strategic Marketing Program with GlamTech USA, Inc. for the Distribution of Glamsmile™ in the United States and Canada”

 

*		Application has been made to the Securities and Exchange Commission to seek confidential treatment of certain portions of this Exhibit 10.1 under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omitted material for which confidential treatment has been requested has been filed separately with the Securities and Exchange Commission.